# Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel

> **NCT01863680** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 178 (actual)

## Conditions studied

- Luteal Hormone Supplementation in In-vitro Fertilization
- Embryo Transfer

## Interventions

- **DRUG:** COL-1620
- **DRUG:** Gonadotropin-releasing hormone (GnRH) analogue
- **DRUG:** Follicle-stimulating hormone (FSH)
- **DRUG:** Human Chorionic Gonadotropin (hCG)

## Key facts

- **NCT ID:** NCT01863680
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2015-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863680, "Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01863680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*